Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Authors

Ying‐Ming Jou
Thomas Scharnitz (ORCID: https://orcid.org/0000-0003-3070-4626)
Catarina Rodrigues Rosa De Oliveira (ORCID: https://orcid.org/0000-0001-9178-8902)
April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
Leon Kircik (ORCID: https://orcid.org/0000-0002-0831-2151)
Carolin Daamen
Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
John Vaile (ORCID: https://orcid.org/0000-0003-3540-0648)

Institutions

Henry Ford Health System (US)
University of California, Los Angeles (US)
Yale University (US)
Bristol-Myers Squibb (United States) (US)
Los Angeles Medical Center (US)
Central Dermatology (US)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-03-20
DOI: https://doi.org/10.1007/s13555-025-01362-w
Citations: 2
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 1.59

Funders

Bristol-Myers Squibb

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Ying‐Ming Jou, Thomas Scharnitz, Catarina Rodrigues Rosa De Oliveira, April Wang Armstrong et al.

Mar 20, 2025

2 citations

Dermatology and Therapy

Psoriasis: Treatment and Pathogenesis

1.59

article

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Ying‐Ming Jou, Thomas Scharnitz, Catarina Rodrigues Rosa De Oliveira, April Wang Armstrong, Mark Lebwohl, Linda Stein Gold, Leon Kircik, Carolin Daamen, Bruce E Strober, John Vaile

March 20, 2025article en

2 citations

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(4)

Henry Ford Health System (US), University of California, Los Angeles (US), Yale University (US), Bristol-Myers Squibb (United States) (US), Los Angeles Medical Center (US), Central Dermatology (US), Icahn School of Medicine at Mount Sinai (US)

Bristol-Myers Squibb

Zero hunger

Openalex Percentile: Top 18%

Psoriasis: Treatment and Pathogenesis

1.59

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials — Ying‐Ming Jou, Thomas Scharnitz, et al. · Dermatology and Therapy (2025) | TGRS Research Map | TGRS